Buserelin vs Gonadorelin (GnRH)
A synthetic GnRH agonist that suppresses hormones to help treat prostate cancer, endometriosis, and infertility
The master hormone that controls your reproductive system and fertility
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Buserelin
200–200 mcg
Gonadorelin (GnRH)
100–100 mcg
Frequency
Buserelin
Once daily
Gonadorelin (GnRH)
Once daily
Administration
Buserelin
Subcutaneous injection
Gonadorelin (GnRH)
Subcutaneous injection
Cycle length
Buserelin
Ongoing/indefinite
Gonadorelin (GnRH)
Ongoing/indefinite
Onset speed
Buserelin
Moderate (1-2 weeks)
Gonadorelin (GnRH)
Moderate (1-2 weeks)
Evidence level
Buserelin
Strong human trials (Phase 3 or FDA approved)
Gonadorelin (GnRH)
Moderate human trials (Phase 1-2)
Benefit ratings
Hormone Suppression
Cancer Management
Fertility Support
Reproductive Health
Hormone Balance
Ovulation Support
Compound specifications
Buserelin
Molecular formula
C60H86N16O13
Molecular weight
1239.4 g/mol
Half-life
2-4 hours (subcutaneous), 30-60 minutes (intranasal); longer for depot formulation (28-40 days)
Bioavailability
~1% (oral); ~10-15% (intranasal); ~95% (subcutaneous)
CAS number
57773-65-6
Gonadorelin (GnRH)
Molecular formula
C55H75N17O13
Molecular weight
1182.3
Half-life
2-4 minutes
Bioavailability
Varies by route: ~5-20% (intranasal), 100% (IV/IM injections)
CAS number
34973-08-5
Dosing compared
Buserelin
Subcutaneous
500 mcg
Every 8 hours (3 times daily) · First 7 days
The product label starts prostate cancer treatment with 500 mcg under the skin every 8 hours for the first week [5].
200 mcg
Once daily · Ongoing maintenance
After the first week, the label switches to 200 mcg once daily under the skin for ongoing treatment [5].
Intranasal
400 mcg (2 sprays per nostril)
3 times daily (1,200 mcg/day) · Ongoing maintenance
The nasal spray option delivers 400 mcg three times a day as maintenance, an alternative to daily injections [5].
Implant
6.3 mg
Once every 2 months · Long-term
A long-acting implant placed under the skin slowly releases buserelin over about 2 months, so no daily dosing is needed [5].
9.45 mg
Once every 3 months · Long-term
A larger implant lasts about 3 months between placements [5].
Gonadorelin (GnRH)
Subcutaneous
100 mcg
Single dose · One-time diagnostic test
FDA-labeled gonadotropin (LH/FSH) stimulation test for pituitary reserve; 100 mcg given once subcutaneously (or IV), with LH measured at 0, 15, 30, 45, 60 and 120 minutes (Factrel) [4].
Intravenous
5 mcg per pulse (range 1-20 mcg)
Every 90 minutes via pulsatile pump · One or more ovulatory cycles; reassessed at 21-day intervals
FDA-labeled pulsatile regimen for ovulation induction in hypothalamic amenorrhea (Lutrepulse); intravenous pulsatile delivery gave better results than subcutaneous [5]. The 2-4 minute half-life makes pulsatile delivery essential.
Best suited for
Buserelin
Managing advanced prostate cancer
Buserelin is particularly well-suited for individuals focused on managing advanced prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Treating endometriosis and reducing associated pain
Buserelin is particularly well-suited for individuals focused on treating endometriosis and reducing associated pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Optimizing ovarian response during fertility treatments
Buserelin is particularly well-suited for individuals focused on optimizing ovarian response during fertility treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Gonadorelin (GnRH)
Improving fertility and conception chances
Gonadorelin (GnRH) is particularly well-suited for individuals focused on improving fertility and conception chances. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Regulating irregular menstrual cycles
Gonadorelin (GnRH) is particularly well-suited for individuals focused on regulating irregular menstrual cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Enhancing reproductive hormone levels
Gonadorelin (GnRH) is particularly well-suited for individuals focused on enhancing reproductive hormone levels. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting natural pregnancy attempts
Gonadorelin (GnRH) is particularly well-suited for individuals focused on supporting natural pregnancy attempts. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Side effects
Buserelin
Gonadorelin (GnRH)
Common
- Mild headache
- Local injection site reactions (redness, swelling)
- Temporary hot flashes
- Mood changes or emotional sensitivity
- Nausea or mild stomach upset
- Allergic skin reactions
- Dizziness or lightheadedness
- Temporary changes in vision
- Joint or muscle aches
- Insomnia or sleep disturbances
- Severe allergic reactions (difficulty breathing, swelling)
- Severe hormonal imbalance symptoms
- Ovarian hyperstimulation syndrome (OHSS)
- Signs of blood clots (chest pain, leg swelling)
- Severe mood changes or depression
Serious
- Severe allergic reaction
Safety & evidence
Buserelin
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for other use
Safety overview
Buserelin is an FDA-approved GnRH agonist with safety data from Phase 3 trials and decades of clinical use, but carries well-documented risks from intentional testosterone/estrogen suppression. The initial testosterone flare (first 2-3 weeks) can worsen prostate cancer symptoms and cause tumor flare pain in 10-20% of patients. Long-term use causes bone density loss of 2-3% annually, with vertebral fractures in 10-20% of long-term users. Cardiovascular risks include increased MI and stroke in men over 65. Hot flashes affect 40-80%, erectile dysfunction is nearly universal, and liver enzyme elevations occur in 5%. Nasal spray formulation causes local irritation in 20-30% of users.
Contraindications
- Pregnancy or breastfeeding
- Hypersensitivity to GnRH agonists
- Certain bone diseases when long-term use is planned
Gonadorelin (GnRH)
Evidence level
Moderate human trials (Phase 1-2)
FDA status
FDA approved for this use
Safety overview
Gonadorelin is native GnRH and carries the safety profile established over 40+ years of clinical use in reproductive endocrinology. As the body's natural hormone, it produces minimal local side effects when dosed appropriately. The critical safety concern with gonadorelin is the initial flare effect within 24-48 hours of first dose—temporary elevation in FSH and LH—which can paradoxically suppress sex hormones before the desired stimulation occurs. This flare makes gonadorelin unsuitable for some conditions and explains why synthetic analogs (agonists, antagonists) are preferred in many modern fertility protocols.
Contraindications
- Pregnancy or breastfeeding
- Hormone-sensitive cancers (breast, prostate, ovarian)
- Severe pituitary or hypothalamic disease
- Undiagnosed abnormal vaginal bleeding
- Known hypersensitivity to GnRH
Which is right for you?
Choose Buserelin if...
- Managing advanced prostate cancer
- Treating endometriosis and reducing associated pain
- Optimizing ovarian response during fertility treatments
Choose Gonadorelin (GnRH) if...
- Improving fertility and conception chances
- Regulating irregular menstrual cycles
- Enhancing reproductive hormone levels
- Supporting natural pregnancy attempts